SPDR S&P Telecom ETF (XTL)
NYSEArca - NYSEArca Real Time Price. Currency in USD
- PR Newswire•16 days ago
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has filed a new patent application with the U.S. Patent and Trademark Office to protect doses of hCDR1 lower than 0.5 mg weekly, in the treatment of Systemic Lupus Erythematosus (SLE). The new patent application is based on clinical evidence that lower doses of hCDR1 may be as efficient, or in some instances more efficient, than the higher doses previously tested in the treatment of SLE. "We are pleased to expand the intellectual property assets around hCDR1, based on clinical data showing hCDR1 may be effective at doses lower than the 0.5 mg weekly, which has shown statistically significant efficacy as compared to placebo in a prior Phase 2 study," said Josh Levine, CEO of XTL.
- MarketWatch•19 days ago
One worry about the U.S. stock market has been that its stars have been defensive sectors. That concern now may be fading, as analysts cheer the recent strength shown by tech, financials and other “cyclical” ...